Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome

NCT00542828 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated due to slow enrollment.

Conditions

Myelodysplastic Syndrome (MDS)

Interventions

BIOLOGICAL: Thymoglobulin®, Rabbit Anti-thymocyte Globulin (rATG)

Sponsor

Genzyme, a Sanofi Company